




Entreprendre pour vaincre le cancer

Fondation d'Utilité Publique reconnue par Arrêté Royal en 2008





DuBuisson



Our mission

Guiding Cancer Researchers into Clinical Practice toward delivery

“Recognize and support entrepreneurs and entrepreneurial researchers who are willing to develop solutions which will be significantly beneficial to the medical community and cancer patients.”



Moving discoveries forward from **Bench to Bedside**





Founder – President

- Bernard Majoie, PhD
 - Pharmacist , PhD in Pharmacology
 - CSO, CEO and finally Chairman of the Board at Laboratories FOURNIER, a family owned mid-size pharmaceutical company
 - Owner at Blue Medical
 - Founder & President of Fournier-Majoie Foundation
- Personal goal
 - To support research, notably in the domain of early detection and/or identification and prognosis of cancer
 - Passing on his experience as an entrepreneur



Scientific & Investment Advisory board



Professor
Martine
PICCART, MD
Chairman
Bordet Institute



Professor
Ferdinand
LEJEUNE, MD
UNI Lausanne




Ass professor
Marc BUYSE,
PhD
Founder of IDDI



Professor
Dominique BRON,
MD
Bordet Institute



Vincent G.
BRICHARD,
MD, Ph.D., MBA
Partner at LSP



Jan PANSEART
CEO/CIO
Founder of
Valiance Asset
Management



Board of Directors



Bernard MAJOIE PhD in Pharmacology
President & Founder

40 y of pharma industry experience , mainly at Lab Fournier



François CHARLET
Business Law degree, Master in Business and Taks Law

Managing Director of various banking institutions



Jérôme MAJOIE
Business School degree, MBA

14y pharma industry experience



Rudy DEKEYSER
PhD

Ex VIB and now LSP
Venture Parner



Paul VAN DUN
Law degree

Managing Director
KULeuven Research & Development



Frédéric GALLAND
HEC Management

Insurance and Finances



Venture Philanthropy

Our model

Donors are due to know FFM drives the teams toward concrete achievements

- **Financial supports:**

- Grant, equity, convertible loan, straight loan
- Average 300 000 € per project
- Mean duration 5 years or more, renewable supports possible


- **Non-financial support:**

- Steering Committees min 4/years
- Achieved milestones driven instalments
- Technical support & networking
- Project management (Market study, Coaching, Business development, ...)

- **Commitment: Return on mission only in case of success**



Vertuous Circle






Selection criteria

Applicable to call for projects and spontaneous applications tackling Cancer:
Biomarkers (Diagnostic, Prognostics, Theragnostics, Companion diagnostics),
Medical Imaging, Therapeutics, Artificial Intelligence, Platform

- Reaching unmet medical needs
- Useful to medical practice
- In vivo POC or prototypes validated
- Preferably non-invasive innovation
- Patient's benefit
- Secured IP
- Co-founding

PROGNOSTIC	DIAGNOSTIC	PREDICTIVE	THERAGNOSTIC	PLATFORM	SOCIAL INITIATIVE
2007 Prostate	2007 Breast	2012 Head & Neck Glioblastoma	2013-2016-2017 Start up Biogazelle	2018 - Start up ATB Therapeutics New immunotherapy	2014 – Start up Esperity
2007 Liver	2008 Brain & Glioblastoma		2015-2016-2017 Start up Camel IDS		
2008-2009-2015 Neuroblastoma 					
2009 -2013-2016 Phospholipids profiling: Prostate Lung Kidney Renal					
2000-2010-2011 Colorectal 2017 – DNAlytics					

Over the last 11 years:

More than 180 projects were evaluated
17 laureates nominated and participation in 5 start-up companies
Cancer Research Institute Ghent partnership : 500k

2017 Partnerships:

Colorectal Cancer Kit Pr. Mazzone with DNAlytics – Colonokit
Hepatotest Pr. Callewaert with Helena Ltd.

2017-2018 Laureates:

ATB Therapeutics: Convertible loans
DNAlytics: Loan and convertible loans



Our partners

ORGANISATIONS

BioWin
 THE HEALTH CLUSTER OF NO-LCIBS
 EORTC
 European Organisation for Research and Treatment of Cancer
 The future of cancer therapy
 KU LEUVEN
 RESEARCH & DEVELOPMENT
 institutCurie
 CRIG
 Member of FlandersBio
 Building Biotech Bridges
 sopartec
 Making science investible
 MATWIN
 MATURATION & ACCELERATED TRANSLATION WITH INDUSTRY
 Center for Medical Innovation
 CMI
 VIB
 Biofit
 FOSTERING INNOVATION & TRANSFER
 TechTransfer

Camel-IDS
 STRIKE THE CANCER, NOT THE PATIENT
 ATB Therapeutics
 biogazelle
 accelerating your discoveries
 DNalytics

COMPANIES

qarad
 esperity
 Educating, Engaging & Empowering Cancer Patients
 Fondation Fournier-Majoie
 pour l'innovation
 Entreprenre pour vaincre le cancer

FOUNDATIONS

King Baudouin Foundation
 Working together for a better society
 espeRare foundation
 Anticancer Fund
 tegan Kanker
 Fondation contre le Cancer
 Fondation d'utilité publique

Loterie Nationale
 Qbic FUND
 PMV
 DOE- EN DURFBEDRIJF
 Caring Entrepreneurship Fund
 Managed by the King Baudouin Foundation

COFINANCING





An example of one of FFM's laureate:



Camel-IDS

STRIKE THE CANCER, NOT THE PATIENT

- Camel-IDS develops targeted radionuclide therapeutic solutions for cancer patients, aimed at fast and specific delivery of therapeutic radiation to selected receptors on the cancer cell surface, while sparing healthy tissues.
- Camel-IDS uses single-domain antibody fragments of Camelidae heavy-chain antibodies (called VHHs or sdAbs) as transport vehicles for radioisotopes.





- October 14th 2014: Incorporation of Camel IDS, by 6 founders. exploiting a technology platform : Personalized radionuclide targeted against cancer.
- Staff team leaded by Tony Lahoutte operates with the VUB laboratories at UZ Jette medical campus with access to medicine facilities and equipment's.
- Dec 2014: Non dilutive funding 947 000€ research grant from Brussels Region (Innoviris) for preclinical experiments and a first in human bio-distribution study of CAM-H2
- June 2015: License agreement with VUB, establishing Camel IDS as Spin off of VUB; Entry of VUB as shareholder
- July 2015: Seed A financing round of 1,4 Million Euro. FFM + 3 Bas as new shareholders.
- December 2015: Second non dilutive funding grant of 1M€ for CAM Alpha and CAM Beta development
- October 2016 Initiation of Phase I Cam –H2
- February 2017 Seed B bridge financing of 1M€
- July 2017: Completion of Phase I trial
- September 2017: Arrival of Ruth Devenyns as new CEO (former CFO of Ogeda) and Series A financing process started
- June 2018: Lead investors secured – Syndicates investors under structuration
- October 2018: Signature of term sheet

FINANCIAL PARTICIPATION OF THE FOUNDATION nearly 500 000 € over 3 years



Braking News: 15 November 2018

Completion 37 Millions Euros series A financing to develop cancer-targeted radiopharmaceuticals:

- Led by V-Bio Ventures (Belgium) and GIMV (Belgium)
- Joined by the co-lead investors HealthCap (Sweden), Novo Seed (Denmark), Pontifax (Israel) and BioMedPartners (Switzerland)
- Past investors participated as well (FFM: 105 000 € additional)
- Proceeds :
 - Run a Phase Ib/II trial CAM-H2, in HER-2 positive brain metastatic breast cancer,
 - Further progress and broaden its preclinical pipeline



From Researcher to Entrepreneur ...

*« Quand on veut on peut,
quand on peut on doit. »*

Napoléon Bonaparte



From Researcher to Entrepreneur ...

Du Ribicon ... à l'Arno !!



THANK YOU

www.fournier-majoie.org

[**info@fournier-majoie.org**](mailto:info@fournier-majoie.org)